How many deals or partnerships with an upfront payment over $500M on aging-biology assets will happen from Jul 2026 to Jul 2027?
Chance it happens
67%Belief the predicted event happens at all — every “yes / by-a-date” outcome added together. “Other” is tracked as its own third slice.
Outcomes
Resolution criteria
Counts disclosed deals, licenses or acquisitions where the UPFRONT payment — cash paid at close — exceeds $500M, on an asset explicitly targeting aging biology, in the window Jul 2026 to Jul 2027. Contingent value does NOT count toward the $500M: milestone payments, royalties, options, earn-outs and CVRs (the biobucks part of the headline) are excluded even when the total announced deal value is far higher. For an acquisition, use the consideration actually paid, excluding CVRs. Resolution horizon: 2027-07-31. Source: press releases, regulatory filings, industry reports.
Description
Aging-biology assets: senolytic, mTOR, NLRP3, autophagy, reprogramming, stem-cell frailty. Upfront = cash that actually changes hands at signing, not biobucks (milestones, royalties, options or contingent value rights that may never be paid).
Evidence & context
Trials, publications and reports our research found on this prognosis. Each links to the original source.
This is a Fight Aging! news/commentary post summarizing NewLimit's $435 million Series C financing and its progress toward human trials in partial reprogramming, an aging-biology area. It does not itself meet the resolution criteria because it is a financing round below the $500M upfront threshold rather than a qualifying deal, but it is relevant background on market appetite and maturity of aging-biology assets.
This is a news report on an $80M Series D financing for Life Biosciences to advance an anti-aging gene therapy into clinical testing. It is relevant as background evidence on capital formation and commercial activity in aging-biology assets, but it is not itself a qualifying >$500M upfront deal, license, partnership, or acquisition.
This is a 2025 company press release about publication of clinical evidence for UNITY's senolytic program, an aging-biology modality. It is not a deal announcement, but it is relevant background because stronger clinical validation of aging-biology assets could increase the likelihood of large partnering or acquisition activity in the forecast window.
This appears to be a company statement from UNITY Biotechnology about strategic actions and a focus on senolytic programs, which are explicitly tied to aging biology. It is relevant as background evidence on the aging-biology asset landscape, though it does not itself disclose a qualifying >$500M upfront deal.
This is a research profile on Retro Biosciences and the aging-biology sector, including competitors such as Altos Labs, NewLimit, and Cambrian Bio. It provides background on the maturity, funding, and strategic landscape of aging-biology companies, which is indirectly useful for estimating the likelihood of large upfront partnering or M&A deals in the target window, but it does not report a qualifying deal itself.